(Q37248229)

English

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma

scientific article published on 04 February 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

head and neck squamous cell carcinoma

0 references

0 references

1 reference

based on heuristic

inferred from title

Hugo Arias-Pulido

object named as

Hugo Arias-Pulido

2

0 references

Elana J. Fertig

object named as

Elana Fertig

6

0 references

author name string

Julie E Bauman

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sang-Joon Lee

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

M Houman Fekrazad

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Hiroyuki Ozawa

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Jason Howard

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Justin Bishop

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Hao Wang

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Garth T Olson

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Michael J Spafford

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Dennie V Jones

12

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Christine H Chung

13

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

4 February 2013

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

49

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

461-467

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Epidermal growth factor receptor is essential for Toll-like receptor 3 signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

mTOR regulates T-cell differentiation and activation in immunity and autoimmunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

The mutational landscape of head and neck squamous cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Immune suppression in head and neck cancers: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Circulating mutant DNA to assess tumor dynamics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Creating oral squamous cancer cells: a cellular model of oral-esophageal carcinogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

6 September 2017

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

14 September 2017

Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

14 September 2017

PIK3CA mutations in head and neck squamous cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

14 September 2017

Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

14 September 2017

Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

14 September 2017

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

14 September 2017

Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

26 June 2018

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

26 June 2018

Evaluation of lymph nodes with RECIST 1.1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

3 September 2018

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

3 September 2018

Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805493

3 September 2018

Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23384718

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/23384718

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23384718

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PTEN expression and methylation status in oral squamous cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23384718

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of secondary lymphedema in patients with head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23384718

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.ORALONCOLOGY.2012.12.016

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37248229&oldid=2106394347"